Literature DB >> 2197713

The role of estrogens in schizophrenia gender differences.

M V Seeman1, M Lang.   

Abstract

The male/female differences that have been described in schizophrenia are important because they may ultimately shed light on factors that mediate the expression of schizophrenic illness. The hypothesis of this article is that estrogens, either directly or indirectly, modify symptom expression and account for many of the observed gender differences. The role of sex hormones is divided into organizational and activational effects. Organizational effects take place during a critical period in fetal life and put a permanent stamp on the developing brain. Activational effects are the direct influences of circulating hormones that appear when hormonal levels rise, and wane when hormonal levels drop. Because levels of sex hormones in adult women fluctuate during the menstrual cycle, cyclic effects of high and low female hormones may induce specific responses by the adult female brain. All these effects have implications for genetic, environmental, pharmacological, neurocognitive, clinical, and epidemiological research in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2197713     DOI: 10.1093/schbul/16.2.185

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  65 in total

Review 1.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

Review 2.  Improving outcome in schizophrenia: the case for early intervention.

Authors:  A K Malla; R M Norman; L P Voruganti
Journal:  CMAJ       Date:  1999-03-23       Impact factor: 8.262

3.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

4.  Identifying 5 Common Psychiatric Disorders Associated Chemicals Through Integrative Analysis of Genome-Wide Association Study and Chemical-Gene Interaction Datasets.

Authors:  Shiqiang Cheng; Yan Wen; Mei Ma; Lu Zhang; Li Liu; Xin Qi; Bolun Cheng; Chujun Liang; Ping Li; Om Prakash Kafle; Feng Zhang
Journal:  Schizophr Bull       Date:  2020-04-15       Impact factor: 9.306

5.  Sex differences, hormones, and fMRI stress response circuitry deficits in psychoses.

Authors:  Jill M Goldstein; Katie Lancaster; Julia M Longenecker; Brandon Abbs; Laura M Holsen; Sara Cherkerzian; Susan Whitfield-Gabrieli; Nicolas Makris; Ming T Tsuang; Stephen L Buka; Larry J Seidman; Anne Klibanski
Journal:  Psychiatry Res       Date:  2015-03-31       Impact factor: 3.222

Review 6.  Estrogen control of central neurotransmission: effect on mood, mental state, and memory.

Authors:  G Fink; B E Sumner; R Rosie; O Grace; J P Quinn
Journal:  Cell Mol Neurobiol       Date:  1996-06       Impact factor: 5.046

7.  Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats.

Authors:  B Meyers; A D'Agostino; J Walker; M F Kritzer
Journal:  Neuroscience       Date:  2009-11-10       Impact factor: 3.590

8.  First-contact rate for schizophrenia in community psychiatric care. Consideration of the oestrogen hypothesis.

Authors:  R K Salokangas
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

Review 9.  Schizophrenia and oestrogens--is there an association?

Authors:  A Riecher-Rössler; H Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

10.  Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants.

Authors:  Hsien-Yuan Lane; Yue-Cune Chang; Chih-Chiang Chiu; Sue-Hong Lee; Cher-Yeang Lin; Wen-Ho Chang
Journal:  Psychopharmacology (Berl)       Date:  2003-12-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.